1223 - Hyperbaric oxygenation and EP (cisplatin and etoposide) chemotherapy in treatment of patients with advanced non small cells lung cancer (NSCLC)

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anti-Cancer Agents & Biologic Therapy
Supportive Care
Non-Small-Cell Lung Cancer, Metastatic
Presenter Mikhail Kopp
Authors M.V. Kopp1, I.A. Koroleva1, S.V. Kozlov2, L.V. Shaplygin3, M.E. Popova1, J.G. Kutyreva1
  • 1Chemotherapy, Samara Regional Clinical Oncology Dispensary, 443031 - Samara/RU
  • 2Oncological, Samara State Medical University, 443031 - Samara/RU
  • 3Head Doctor, Samara Oncology Center, 4430131 - Samara/RU

Abstract

Background

By the time of diagnosis more than 75% of all lung cancer patients have locally advanced or metastatic process. According to WHO, at different stages of treatment to 80% of lung cancer patients need chemotherapy. Malignant neoplasm lead to the development of tissue oxygen deficiency or directly related to acute or chronic hypoxia. Hypoxia of normal tissue is one of the reasons of chronic anemia in patients with advanced NSCLC. We conducted an analysis of toxicity of chemotherapy in patients with advanced NSCLC by means of chemotherapy concurrently with hyperbaric oxygenation.

Materials and methods

Between October 2010 and March 2012 63 patients with advanced NSCLC were treated with EP chemotherapy regimen (Cisplatin 75mg/m2 on day 1 + Etoposide 120mg/m2 in 1, 3, 5 days). Cycles repeated every 21 days. We used two hyperbaric pressure chamber: BLKS 303MK and BLKS-307 Khrunichev. Hyperbaric oxygenation procedures are held under pressure 1.3 atm for 40 minutes, 1 time a day every day for 5 consecutive days. All the patients were divided into 2 groups. 28 patients received chemotherapy only. 35 patients received chemotherapy simultaneously with hyperbaric oxygen therapy. Patients were not given any prophylaxis of neutropenia. Toxicity was evaluated with Common Toxicity Criteria, Version 3.0.

Results

Grade 2 anemia was reported in 29% patients treated with chemotherapy and hyperbaric oxygenation and in 43% patients treated with chemotherapy only. The beneficial effect of hyperbaric oxygenation was also demonstrated by a quick recovery of hemoglobin level than in control. We evaluated the dose intensity of chemotherapy. Dose reductions and increased periods between cycles of chemotherapy are associated with poor outcomes of chemotherapy. Dose intensity in patients received chemotherapy with hyperbaric oxygenation was 91%, but in the group of chemotherapy only dose intensity was 79%. We did not observed any specific side effects of hyperbaric oxygenation.

Conclusions

The results show that hyperbaric oxygenation procedures with the chemotherapy n reduced grade of anemia in patients with advanced NSCLC.

Disclosure

All authors have declared no conflicts of interest.